RxDoctor Payments Data

Sunil Lalla, MD

Pulmonary Disease · Fort Myers, FLNPI 1407841760

Payments from drug & device makers

$8,334in general payments, 2019–2025

Across 53 payments — averaging $157.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$7K
  • Johnson & Johnson$322
  • Pulmonx Corporation$186
  • AstraZeneca$154
  • Sanofi$132
  • Covidien LP$116
  • plus $429 from 13 others

What the payments were for

  • Travel & lodging$92811%
  • Food & beverage$1,36816%
  • Education$6,01772%
  • Gifts$220%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,334 in reported general payments places this provider in the 60th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$493,045
Medicare patients
578
Services billed
4,508

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan12$154,085
Trelegy ElliptaFluticasone/Umeclidin/Vilanter51$65,871
EliquisApixaban27$34,442
Breztri AerosphereBudesonide/Glycopyr/Formoterol27$29,422
Breo ElliptaFluticasone/Vilanterol35$27,802
OzempicSemaglutide15$27,066
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr21$25,297
JanuviaSitagliptin Phosphate13$13,092
MounjaroTirzepatide11$11,545
SymbicortBudesonide/Formoterol Fumarate22$11,189
Combivent RespimatIpratropium/Albuterol Sulfate14$10,749
Albuterol Sulfate HfaAlbuterol Sulfate202$5,511
BreynaBudesonide/Formoterol Fumarate11$2,309
Ventolin HfaAlbuterol Sulfate37$2,034
Ranolazine ErRanolazine14$1,105

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit$49$154,08512 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$56$118,970107 claims
AstraZenecaBreztri Aerosphere, Symbicort$154$40,61149 claims
MerckJanuvia$92$13,09213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →